受强制性开放获取政策约束的文章 - Omar Alhalabi了解详情
无法在其他位置公开访问的文章：6 篇
Progression of disease after bacillus Calmette-Guérin therapy: refining patient selection for neoadjuvant chemotherapy before radical cystectomy
PJ Hensley, KK Bree, MT Campbell, O Alhalabi, A Kokorovic, T Miest, ...
The Journal of Urology 206 (5), 1258-1267, 2021
强制性开放获取政策： US National Institutes of Health
Outcomes of patients with intermediate‐risk or poor‐risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of …
O Alhalabi, E Hasanov, NR Wilson, J Araujo, J Wang, MT Campbell, ...
International journal of cancer 149 (2), 387-393, 2021
强制性开放获取政策： US Department of Defense, US National Institutes of Health
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract
O Alhalabi, N Wilson, L Xiao, Y Lin, J Khandelwal, MJ Moussa, P Msaouel, ...
European Urology Oncology 6 (6), 611-620, 2023
强制性开放获取政策： US Department of Defense, US National Institutes of Health, Patient-Centered …
Evolving systemic management of urothelial cancers
WS Tan, MY Tan, O Alhalabi, MT Campbell, AM Kamat, J Gao
Current opinion in oncology 35 (3), 186-199, 2023
强制性开放获取政策： US Department of Defense, US National Institutes of Health, Doris Duke …
Phase 1b Trial Evaluating Tolerability and Activity of Targeted FGFR Inhibition in Localized Upper Tract Urothelial Carcinoma
SF Matin, M Adibi, AY Shah, O Alhalabi, P Corn, C Guo, R Amirtharaj, ...
Journal of Urology, 10.1097, 2024
强制性开放获取政策： US National Institutes of Health
Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials
O Alhalabi, AW Hahn, P Msaouel, F Meric-Bernstam, N Wilson, A Naing, ...
Clinical Genitourinary Cancer 20 (1), e16-e24, 2022
强制性开放获取政策： US Department of Defense, US National Institutes of Health
可在其他位置公开访问的文章：20 篇
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma
J Gao, N Navai, O Alhalabi, A Siefker-Radtke, MT Campbell, RS Tidwell, ...
Nature medicine 26 (12), 1845-1851, 2020
强制性开放获取政策： US National Institutes of Health
Factor XII and uPAR upregulate neutrophil functions to influence wound healing
EX Stavrou, C Fang, KL Bane, AT Long, C Naudin, E Kucukal, A Gandhi, ...
The Journal of clinical investigation 128 (3), 944-959, 2018
强制性开放获取政策： US National Institutes of Health, US Department of Veterans Affairs …
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
G Han, G Yang, D Hao, Y Lu, K Thein, BS Simpson, J Chen, R Sun, ...
Nature communications 12 (1), 5606, 2021
强制性开放获取政策： US National Institutes of Health, Cancer Research UK, UK Medical Research …
Reduced thrombosis in Klkb1−/− mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor
EX Stavrou, C Fang, A Merkulova, O Alhalabi, N Grobe, S Antoniak, ...
Blood, The Journal of the American Society of Hematology 125 (4), 710-719, 2015
强制性开放获取政策： US National Institutes of Health
Prognostic factors in patients with metastatic breast cancer with bone‐only metastases
A Parkes, CL Warneke, K Clifton, A Al‐Awadhi, O Oke, RC Pestana, ...
The oncologist 23 (11), 1282-1288, 2018
强制性开放获取政策： US National Institutes of Health
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers
O Alhalabi, J Chen, Y Zhang, Y Lu, Q Wang, S Ramachandran, ...
Nature communications 13 (1), 1797, 2022
强制性开放获取政策： US National Institutes of Health, Doris Duke Charitable Foundation
A Cross-sectional Study of KLKB1 and PRCP Polymorphisms in Patient Samples with Cardiovascular Disease
HR Gittleman, A Merkulova, O Alhalabi, EX Stavrou, ML Veigl, ...
Frontiers in Medicine 3, 17, 2016
强制性开放获取政策： US National Institutes of Health
Efficacy of cabozantinib in metastatic MiT family translocation renal cell carcinomas
J Thouvenin, O Alhalabi, M Carlo, L Carril-Ajuria, L Hirsch, ...
The Oncologist 27 (12), 1041-1047, 2022
强制性开放获取政策： US National Institutes of Health
Integrative clinical and genomic characterization of MTAP-deficient metastatic urothelial cancer
O Alhalabi, Y Zhu, A Hamza, W Qiao, Y Lin, RM Wang, AY Shah, ...
European urology oncology 6 (2), 228-232, 2023
强制性开放获取政策： US National Institutes of Health, Doris Duke Charitable Foundation
Revisiting Treatment of Metastatic Urothelial Cancer: Where Do Cisplatin and Platinum Ineligibility Criteria Stand?
MJ Moussa, MT Campbell, O Alhalabi
Biomedicines 12 (3), 519, 2024
强制性开放获取政策： US Department of Defense
Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes
O Alhalabi, AW Hahn, P Msaouel, AY Andreev-Drakhlin, ...
Molecular Cancer Research 19 (3), 395-402, 2021
强制性开放获取政策： US National Institutes of Health, Cancer Prevention Research Institute of …
Stranger things: new roles and opportunities for androgen receptor in oncology beyond prostate cancer
J Leo, E Dondossola, KJ Basham, NR Wilson, O Alhalabi, J Gao, ...
Endocrinology 164 (6), bqad071, 2023
强制性开放获取政策： US National Institutes of Health
Landscape of immunotherapy in genitourinary malignancies
D Ravindranathan, O Alhalabi, H Rafei, AY Shah, MA Bilen
Immunotherapy, 143-192, 2021
强制性开放获取政策： US National Institutes of Health
Combinations, Sequencing, and the Contribution of Components: New Frontline Standards for Metastatic Urothelial Carcinoma
AO Siefker-Radtke, D Cauley, O Alhalabi
Journal of Clinical Oncology 41 (25), 4084-4086, 2023
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定